A Phase III clinical trial is underway to develop a safe, effective, and globally accessible therapeutic for dengue. The trial, led by DNDi, involves 1,000 participants across Brazil, Malaysia, and Thailand. Monoclonal antibodies, currently the most advanced dengue treatment candidates, are being tested.
The European Medicines Agency has granted a positive opinion to Acoziborole Winthrop as a single-dose oral treatment for both early- and advanced-stage gambiense sleeping sickness in adults and adolescents. The medicine, co-developed by DNDi and Sanofi, could provide a significant advance over current therapies.
A breakthrough all-oral treatment for a rare but deadly strain of sleeping sickness is now available, revolutionizing care for patients in endemic countries. Fexinidazole Winthrop has been approved for use in several African countries and is being distributed by WHO, offering a safer alternative to existing treatments.
A new, easier-to-administer sustained-release formulation of flucytosine has entered Phase II clinical trials in Malawi and Tanzania. The trial aims to address the growing concern of cryptococcal meningitis, a major health threat to people with weakened immune systems, particularly those with advanced HIV.
A Phase II clinical trial has demonstrated that fosravuconazole is effective in treating mycetoma, a chronic disabling disease. The new oral treatment has been shown to have significant advantages over existing treatments, including a lower pill burden and minimal interactions with other medications.
The Phase II/III study found that acoziborole has an 18-month treatment success rate of 95% for late-stage patients and 100% for early-stage patients, with no significant safety concerns reported. This breakthrough could lead to the elimination of sleeping sickness through a simplified 'screen-and-treat' approach.
A new, shorter combination treatment has been shown to be effective in treating visceral leishmaniasis in Eastern Africa. The treatment, which combines miltefosine and paromomycin, is safer and reduces hospitalization time by 18%, eliminating the need for painful daily injections.
The National Pharmaceutical Regulatory Agency of Malaysia has granted conditional registration to a new hepatitis C treatment combination developed through public-private partnership. The treatment, ravidasvir, was shown to be effective and well-tolerated in clinical trials, with cure rates of up to 97%.
The ANTICOV study is testing a new potential treatment that combines nitazoxanide and ciclesonide to treat people with mild-to-moderate COVID-19. The trial aims to identify early treatments that can prevent progression to severe disease and potentially limit transmission.
A new international coalition aims to accelerate COVID-19 research in resource-poor settings, addressing the urgent need for effective treatments and vaccines. The Coalition will facilitate a coordinated approach to collect data from all regions, enabling rapid evidence-based decisions on policies and practice.
A study by the Drugs for Neglected Diseases Initiative found that nearly 60% of patients with PKDL passed on parasites to sandflies, which can then infect others. Early treatment of PKDL patients is crucial to prevent transmission of leishmaniasis in South Asia.
A two-week treatment course for adult patients with chronic Chagas disease was shown to be as effective as an eight-week standard treatment in improving sustained parasitological response at six months. The new regimen also significantly reduced side effects, encouraging wider adoption by the medical community.
Wellcome and DNDi partner to develop novel, orally administered treatments for leishmaniasis, a devastating parasitic disease affecting one billion people worldwide. The three-year programme aims to select two new chemical entities for Phase II studies, focusing on safety, efficacy, affordability, and administration.
A recent study published in PLOS Neglected Tropical Diseases has shown that combination therapy is highly effective in treating patients with both HIV and visceral leishmaniasis. The treatment regimen, which combines liposomal amphotericin B with the oral drug miltefosine, resulted in a 67% cure rate after 28 days of treatment.
A global review of antibiotic sales in 70 high- and middle-income countries found that consumption patterns vary widely, with low levels of 'Access' antibiotics like amoxicillin. The study also highlights the overuse of 'Watch' antibiotics, which should only be used for specific indications.
FIND and DNDi partner to generate evidence for policy change and scale-up of HCV diagnosis and treatment in Malaysia. Decentralized screening using pre-qualified rapid diagnostic tests will be initiated, linking positive cases to direct-acting antiviral treatment.
The UK government has invested £1m in the Global Antibiotic Research and Development Partnership (GARDP) to accelerate the development of a new treatment for drug-resistant gonorrhoea. This funding will enable sustainable access to the treatment in low- and middle-income countries, where the burden of infection is greatest.
The new treatment combination including ravidasvir and sofosbuvir has shown extremely high cure rates, even among hard-to-treat patients, with a 97% success rate reported in the Phase II/III trial. The treatment is priced affordably at $300 for a 12-week course, offering an alternative to existing treatments.
Gonorrhea is a growing global health crisis with over 60% of countries reporting resistance to last-resort treatments. Gardp and Entasis partner on zoliflodacin, a novel first-in-class oral antibiotic with potent activity against drug-resistant strains.
A landmark study confirms that 'super-boosting' approach effectively counters negative interactions between key HIV and TB drugs in children co-infected with both diseases. This advancement will enable healthcare workers to treat children more effectively, ensuring long-term control of the HIV virus and keeping them alive.
A potentially pan-genotypic combination of ravidasvir and sofosbuvir will be tested in Malaysia and Thailand to treat hepatitis C at a target price of under $300. The treatment, licensed by DNDi, aims to provide an affordable cure for the deadly disease that treats all strains.
The Phase I study confirms the therapeutic dose and safety profile of SCYX-7158, a first oral drug candidate specifically developed to combat human African trypanosomiasis. The study results translate into prolonged exposure with just one dose, targeting the late stage of the disease where the parasite crosses the blood-brain barrier.
The ASMQ FDC has shown non-inferior efficacy to AL FDC in treating uncomplicated falciparum malaria in children under 5 years old. No significant concerns of tolerability were observed with either treatment.
A Phase III clinical study has been initiated in Ethiopia to assess the efficacy and safety of two treatment combinations for HIV-visceral leishmaniasis co-infected patients. The study aims to identify a safe and effective treatment for this life-threatening condition, which affects millions worldwide.
A large-scale roll-out of the combination treatment for kala-azar in Eastern Africa has shown a high efficacy and safety profile, with a 95% cure rate among treated patients. The treatment aims to replace traditional therapies due to toxicity levels and cost concerns.
A Phase II trial is being conducted to test fexinidazole, a 'rediscovered' drug, for its safety and efficacy in treating Chagas disease. The study aims to determine if the drug is safer and more effective than placebo in clearing the parasite that causes the disease.
A Phase 2 clinical trial in Bolivia found that experimental drug candidate E1224 showed good safety and efficacy in clearing the Chagas parasite, but had little sustained efficacy as a single medication. Standard therapy benznidazole was effective but associated with side effects.
A new study found that only 4% of new drugs and vaccines approved between 2000-2011 were for neglected diseases, highlighting a 'fatal imbalance' in R&D efforts. Researchers highlight the need to develop and deliver groundbreaking treatments for poor patients.
The World Health Organization's new guidelines call for immediate antiretroviral therapy (ART) for all HIV-infected children under five years of age. DNDi and Cipla are expediting the development of urgently needed 4-in-1 ARVs adapted for babies and toddlers with HIV, to be delivered by 2015.
The AfriCoLeish project aims to test new treatments for kala-azar and co-infection with HIV in Ethiopia and Sudan, providing a shorter combination treatment option. The project will also determine appropriate treatment strategies for co-infected patients to prevent relapses.
Only a small fraction of new medicines developed between 2000 and 2011 were for the treatment of neglected diseases, highlighting significant gaps in innovation. Despite this, some progress has been made through drug reformulations and repurposing of existing drugs.
DNDi will receive a $17.3 million grant from UNITAID to accelerate the development and delivery of child-adapted antiretroviral therapy (ARV) formulations for babies and toddlers with HIV/AIDS, including those co-infected with tuberculosis. This support aims to improve treatment accessibility and outcomes for young children affected by...
A new $3 million study will investigate biological markers measuring treatment efficacy for Chagas disease. The research seeks to develop a robust test to expand treatment options and accelerate clinical trials for this potentially fatal neglected tropical disease.
The Brazilian Ministry of Health, Oswaldo Cruz Foundation (FIOCRUZ), and Drugs for Neglected Diseases initiative (DNDi) Latin America have partnered to develop new therapies and diagnostics for neglected diseases. This partnership aims to boost innovation in the field and provide new health tools to Brazil's public health programs.
A new collaboration between DNDi and Cipla aims to develop a 4-in-1 ARV combination product for young children with HIV/AIDS, addressing the gap in current treatments. The goal is to provide safe, potent, child-friendly treatment combinations to accelerate care provision for infants and toddlers living with HIV/AIDS.
The Drugs for Neglected Diseases Initiative (DNDi) has received a €2 million Strategic Translation Award from the Wellcome Trust to develop E1224, a pro-drug with potent in vivo and in vitro activity against T. cruzi, the parasite causing Chagas disease.
Key findings: DNDi highlights the need for enhanced research and development for new treatment and diagnostic tools for NTDs. The organization stresses that filling R&D gaps is crucial to achieving disease control or elimination by 2020.
A new combination therapy for kala azar has been developed, reducing treatment time from 30 days to 17 days and decreasing costs. However, without international funding, too few patients will benefit from this new treatment.
DNDi has launched a new programme to develop paediatric HIV treatments, focusing on improving dosing, tolerability and affordability. The initiative aims to fill the unmet treatment gap for millions of children with HIV/AIDS in low- and middle-income countries.
The Drugs for Neglected Diseases Initiative (DNDi) has launched a new research project to develop a macrofilaricidal drug candidate, flubendazole, to treat co-infection of filarial diseases. The project aims to assess the safety profile and reformulate the drug to reduce treatment cycles from 12 years to 2-3 years.